ABSTRACT
Objective To estimate the US incidence of thrombotic events and related rare diagnoses.
Design Claims-based retrospective cohort study of incidence.
Setting US commercial health insurance administrative claims database.
Participants Adults 25-65 years of age between 2015 and 2019 with a minimum of 12 consecutive thrombosis-free months of continuous enrollment beginning 2014 were selected.
Main Outcomes Age (10 year intervals) and sex stratum specific incidence rates per 100,000 person-years were determined for: venous thromboembolism (VTE), cerebral venous thrombosis (CVT), and any major thrombosis. Incidence also was estimated for immune thrombocytopenic purpura (ITP), hemolytic-uremic syndrome (HUS), and heparin-induced thrombocytopenia (HIT).
Results Among approximately 15 million enrollees per year (half female/male), incidence of any thrombotic event (DVT, PE, CVT, or other thrombosis) was 247.89 per 100,000 person-years (95% CI: 245.96, 249.84). Incidence of VTE was 213.79 with ICD codes alone (95% CI: 211.99, 215.59) and 127.18 (95% CI: 125.80, 128.58) when also requiring a filled anticoagulation prescription. Incidence rates were 6.37 for CVT (95% CI: 6.07, 6.69), 26.06 for ITP (95% CI: 25.44, 26.78), 0.94 for HUS (95% CI: 0.82, 1.06), and 4.82 for HIT (95% CI: 4.56, 5.10). The co-occurrence of CVT with either ITP or HIT (diagnoses within 14 days of one another) was 0.090 (95% CI: 0.06, 0.13). Incidence tended to increase with age and was higher for women under 55. Incidence for CVT, HUS, and CVT with ITP or HIT was higher for women in all age groups.
Conclusions These results are the first US estimates for incidence of thrombotic and rare events in a large, commercially-insured US population. Findings provide a critically important reference for determining excess morbidity associated with COVID-19 and more generally for vaccine pharmacovigilance.
What is already known on this topic?
Incidence of thrombosis diagnoses vary by country and date.
There have been improvements in the past decade in thromboprophylaxis (e.g., deep vein thrombosis) and detection (e.g., cerebral venous thrombosis), but there are no recent comprehensive estimates for the United States.
What this study adds
Our results document the US incidence of thrombotic and related rare diagnoses for the most recent five-year pre-pandemic period (2015-2019) using a health insurance administrative claims database with approximately 15 million enrollees per year.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded in part by a grant from the Texas Academy of Family Physicians Foundation (Weller SC: Does Statin Therapy Reduce VTE Due To Hormone Therapy In Post-Menopausal Women?) and in part by the Sealy Institute for Vaccines Sciences (Weller SC, Porterfield, L: Incidence of Thrombotic Events in a Large, Insured US Population).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was overseen by the University of Texas Medical Branch at Galveston Institutional Review Board, and received approval therein.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was funded in part by a grant from the Texas Academy of Family Physicians Foundation (Weller SC: Does Statin Therapy Reduce VTE Due To Hormone Therapy In Post-Menopausal Women?) and in part by the Sealy Institute for Vaccines Sciences (Weller SC, Porterfield, L: Incidence of Thrombotic Events in a Large, Insured US Population).
Data Availability
All available data appear in either the figures or Appendix of this study.
